Cancer Prevention Clinical Trials Monitoring and Informatics Support

美国国家癌症研究所癌症预防部（NCI DCP）支持科学研究，不仅要识别癌症高危人群，还要识别和开发化学预防和其他干预措施，以抑制、减缓、逆转、预防或延缓癌症的发生。NCI DCP管理一系列科学和临床活动，包括确定具有潜在癌症预防活性的药物并对其进行优先排序，选择用于开发的药物，进行临床前研究，进行测试药物的I期和II期试验，以及将有希望的药物推向更大的III期癌症预防临床试验。这些癌症预防试验是由校外研究者在国家和国际临床站点进行的。

The National Cancer Institute Division of Cancer Prevention (NCI DCP) supports science that seeks not only to identify those at high risk of developing cancer, but also to identify and develop chemopreventive and other interventions that will inhibit, regress, reverse, prevent or delay the incidence of cancer. NCI DCP manages a portfolio of scientific and clinical activities which includes identifying and prioritizing agents with potential cancer prevention activity, selecting agents for development, performing pre-clinical studies, conducting Phase I and Phase II trials for testing agents, and moving promising agents into larger Phase III cancer prevention clinical trials. These cancer prevention trials are conducted by extramural investigators at national and international clinical sites. As sponsor of a trial, NCI DCP is responsible for ensuring that clinical trials are conducted safely and according to protocol from the initial safety studies through the definitive evaluation of the role of the new agent or intervention in the prevention of specific types of cancer. Fulfillment of this responsibility requires careful and thorough monitoring of a clinical trial throughout its entire process including the verification of clinical trials data as well as investigator compliance with the protocol, Good Clinical Practice Guidelines and applicable regulatory requirements and clinical trials policies. The Cancer Prevention Clinical Trials Monitoring and Informatics Support contract provides comprehensive clinical trial oversight capability for the Phase 0, Phase I, Phase II, and selected Phase III cancer prevention clinical trials sponsored by NCI DCP.